What is claimed

1. Use of TSL-1502 and another anti-tumor drug selected from carboplatin or irinotecan hydrochloride (CAMPTO) in the manufacture of a pharmaceutical composition for the treatment of cancer, wherein the pharmaceutical composition comprises TSL-1502 and carboplatin in a ratio of 25:60 (mg/kg), or TSL-1502 and irinotecan hydrochloride (CAMPTO) in a ratio of 50:10 (mg/kg), or a combination wherein two pharmaceutical preparations individually containing respective amounts of TSL-1502 and the anti-tumor drug are packaged together.

2. The use of TSL-1502 and another anti-tumor drug selected from carboplatin or irinotecan hydrochloride (CAMPTO) in the manufacture of a pharmaceutical composition for the treatment of cancer according to claim 1, characterized in that, the dose of each drug is in a pharmaceutically effective amount.

3. The use of TSL-1502 and another anti-tumor drug selected from carboplatin or irinotecan hydrochloride (CAMPTO) in the manufacture of a pharmaceutical composition for the treatment of cancer according to claim 1, wherein the compositional pharmaceutical combination is in any ingestible pharmaceutical form, preferably pharmaceutical form being injectable preparation, in unit dose form, with each unit dose comprising 0.1-2000mg of pharmaceutical active ingredients.

4. The use of TSL-1502 and another anti-tumor drug selected from carboplatin or irinotecan hydrochloride (CAMPTO) in the manufacture of a pharmaceutical composition for the treatment of cancer according to any one of claims 1 to 3, wherein the use method comprises the following steps of: preparing the required amount of TSL-1502 and another anti-tumor drug together as two pharmaceutical active ingredients into an injectable preparation for injection, or separately preparing the required amount of TSL-1502 and another antitumor drug into injectable preparations for separate injection.

5. The use of TSL-1502 and another anti-tumor drug selected from carboplatin or irinotecan hydrochloride (CAMPTO) in the manufacture of a pharmaceutical composition for the treatment of cancer according to claim 1, wherein said TSL-1502 and another anti-tumor drug selected from carboplatin or irinotecan hydrochloride (CAMPTO) are prepared by the following steps: preparing the required amount of TSL-1502 and another anti-tumor drug together or respectively as pharmaceutical active ingredients into a pharmaceutical composition which can be taken according to the conventional technology of pharmacy.

6. The use of the TSL-1502 and another anti-tumor drug selected from carboplatin or irinotecan

hydrochloride (CAMPTO) according to claim 5, wherein the dosage form of the compositional pharmaceutical combination is injectable preparation and is prepared without excipients or with one or more pharmaceutically acceptable excipients, selected from a group consisting of glucose, lactose, mannitol, sodium chloride, and hydroxypropyl-B-cyclodextrin.

7. The use of TSL-1502 and another anti-tumor drug selected from carboplatin or irinotecan hydrochloride (CAMPTO) according to any one of claims 1 to 3, wherein the cancer is selected from a group consisting of breast cancer, melanoma, colorectal cancer.